A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROME.

Trial Profile

A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROME.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs OMS 210 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Lotus Pharmaceuticals
  • Most Recent Events

    • 16 Aug 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 14 Jul 2012 Planned number of patients changed from 228 to 417 as reported by European Clinical Trials Database record.
    • 14 Jul 2012 Actual initiation date changed from 23 Jul 2010 to 15 Oct 2010 and primary endpoint added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top